BioCryst Pharmaceuticals Stock News

Small-cap biotech BioCryst Pharmaceuticals (NASDAQ: BCRX) is among them, and its COVID-19 drug is currently in early stage clinical testing. While most companies working on a COVID-19 treatment have

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track des

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, BidAskCl

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

RESEARCH TRIANGLE PARK, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2020 financial results on

SG Americas Securities LLC grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1,399.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC

BioCryst's position has improved on several fronts in the last few months. The company raised cash, reported preliminary positive results of BCX9930 in PNH patients, and there is now upside optionalit

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest

North Star Investment Management Corp. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the

BioCryst’s moonshot probably won’t be as good for shareholders as Moderna’s has already been.

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Brokerages expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post $3.17 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Bio

Stocks Analysis by Harry Boxer covering: BioCryst Pharmaceuticals Inc, Cytokinetics Inc, Vaxart Inc, Novavax Inc. Read Harry Boxer's latest article on Investing.com

There might be a simple explanation for why the company doubled the expected enrollment in its COVID-19 clinical trial.

If you want to know who really controls BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), then you'll have to look at the...